Immatics (NASDAQ:IMTX) to Post FY2024 Earnings of ($1.11) Per Share, Chardan Capital Forecasts

Immatics (NASDAQ:IMTX) – Investment analysts at Chardan Capital issued their FY2024 earnings estimates for shares of Immatics in a research note issued on Monday, July 1st. Chardan Capital analyst Y. Livshits anticipates that the company will post earnings of ($1.11) per share for the year. The consensus estimate for Immatics’ current full-year earnings is ($1.29) per share. Chardan Capital also issued estimates for Immatics’ FY2025 earnings at ($1.15) EPS.

Separately, Mizuho boosted their price target on shares of Immatics from $14.00 to $16.00 and gave the stock a “buy” rating in a research note on Thursday, May 16th.

Immatics Stock Performance

NASDAQ IMTX opened at $11.82 on Thursday. Immatics has a 52-week low of $7.15 and a 52-week high of $13.77. The company has a market capitalization of $1.00 billion, a P/E ratio of -11.15 and a beta of 0.75. The company has a fifty day moving average of $11.60 and a 200-day moving average of $11.38.

Immatics (NASDAQ:IMTX) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.74) by $0.70. Immatics had a negative net margin of 107.80% and a negative return on equity of 29.36%. The company had revenue of $32.87 million during the quarter, compared to the consensus estimate of $17.76 million.

Institutional Trading of Immatics

Several hedge funds have recently added to or reduced their stakes in the business. RA Capital Management L.P. bought a new stake in Immatics in the first quarter worth $18,392,000. Zimmer Partners LP lifted its stake in Immatics by 89.0% in the first quarter. Zimmer Partners LP now owns 397,000 shares of the company’s stock worth $4,172,000 after purchasing an additional 187,000 shares during the last quarter. Baker BROS. Advisors LP lifted its stake in Immatics by 10.4% in the first quarter. Baker BROS. Advisors LP now owns 6,443,398 shares of the company’s stock worth $67,720,000 after purchasing an additional 604,545 shares during the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Immatics by 38.2% during the first quarter. Price T Rowe Associates Inc. MD now owns 3,225,360 shares of the company’s stock valued at $33,899,000 after acquiring an additional 891,191 shares during the last quarter. Finally, Affinity Asset Advisors LLC raised its stake in shares of Immatics by 75.0% during the first quarter. Affinity Asset Advisors LLC now owns 350,000 shares of the company’s stock valued at $3,678,000 after acquiring an additional 150,000 shares during the last quarter. 64.41% of the stock is owned by institutional investors.

Immatics Company Profile

Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.